<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A7E4A556-6F0D-4CCF-97A0-3FA60E38CE8C"><gtr:id>A7E4A556-6F0D-4CCF-97A0-3FA60E38CE8C</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:surname>Gilks</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6905FDCD-0B68-4F42-A07E-17DC8B6B059E"><gtr:id>6905FDCD-0B68-4F42-A07E-17DC8B6B059E</gtr:id><gtr:firstName>Sylvester</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Sempala</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D68B51BA-2D9D-477D-A930-6F655038E659"><gtr:id>D68B51BA-2D9D-477D-A930-6F655038E659</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Whitworth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A6BAEC07-E057-4F0A-933A-BF3E851B5C99"><gtr:id>A6BAEC07-E057-4F0A-933A-BF3E851B5C99</gtr:id><gtr:firstName>Abdel</gtr:firstName><gtr:otherNames>Ghayoum</gtr:otherNames><gtr:surname>Babiker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0000068"><gtr:id>8F2BC2F6-5A6A-4E9A-ACBE-43DF42D2DEAC</gtr:id><gtr:title>Developing of Anti-Retroviral Therapy (DART) in Uganda: 1: pulse and hydroxyurea</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0000068</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1792140</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DART results</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6DBB8F7A-0EDC-48DC-B715-C39B0E41AD85</gtr:id><gtr:impact>The DART Trial has had significant impact on policy for ART. These are detailed in subsequent grants that continued DART</gtr:impact><gtr:outcomeId>Y3xRv3i6uLZ</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>57C3FBDD-05A8-46F7-AB3F-6A0851F51E90</gtr:id><gtr:title>Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96888be17bf947367e44907c170ce926"><gtr:id>96888be17bf947367e44907c170ce926</gtr:id><gtr:otherNames>Kikaire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>MSfifRB17hR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC82EA0E-40DE-4727-81BF-D8A2D8BA14D6</gtr:id><gtr:title>Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_540e132e1328df5fc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DD1CAC4-3A9B-4467-9E0A-E9FF81CF44EA</gtr:id><gtr:title>Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f409e6effa963165e88c95c6b2a649eb"><gtr:id>f409e6effa963165e88c95c6b2a649eb</gtr:id><gtr:otherNames>Reid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_540e132e132833be7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71B7C4C1-0C34-4F5D-BEF0-AC8FB7F4F4EB</gtr:id><gtr:title>Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3417d4ce8ff7e6e00ba6e34e64293c2b"><gtr:id>3417d4ce8ff7e6e00ba6e34e64293c2b</gtr:id><gtr:otherNames>DART Virology Group and Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>cm5R1HRBC1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD99B787-BD7E-43D1-9CCB-F9A7C59E46C1</gtr:id><gtr:title>Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/204b3fba8c82b0d72f21535fc6b103d3"><gtr:id>204b3fba8c82b0d72f21535fc6b103d3</gtr:id><gtr:otherNames>Ssali F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>hfavDLutXhx</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0000068</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>